Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05648110 · ClinicalTrials.gov registry record · Phase 2
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,882
- Enrollment target
NCT05648110 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 3,882 participants.
The verdict
NCT05648110, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,882 participants
- Enrollment target
Study Summary
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061. Sub-study: This Phase II sub-study of SUPERNOVA will assess the safety, PK, and predicted neutralizing activity of AZD3152 compared with EVUSHELD for pre-exposure prophylaxis of COVID-19.
Interventions
- BIOLOGICAL AZD5156 (Parent study Sentinel Safety Cohort)
- BIOLOGICAL Placebo (Parent study Sentinel Safety Cohort)
- BIOLOGICAL EVUSHELD™ (Parent study Main Cohort)
- BIOLOGICAL AZD3152 (Parent study Main Cohort)
- BIOLOGICAL Placebo (Parent study Main Cohort)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,882 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2025-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05648110
The ClinicalTrials.gov registry entry for NCT05648110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3,882 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AZD5156 (Parent study Sentinel Safety Cohort) is the first listed.
NCT05648110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05648110 about?
NCT05648110 is a clinical study titled "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)". AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared ...
What is the current status of trial NCT05648110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,882 participants. The study started on 2022-12-16. Estimated completion is 2025-02-11.
What interventions are being tested in trial NCT05648110?
The interventions under investigation include: AZD5156 (Parent study Sentinel Safety Cohort) (BIOLOGICAL), Placebo (Parent study Sentinel Safety Cohort) (BIOLOGICAL), EVUSHELD™ (Parent study Main Cohort) (BIOLOGICAL), AZD3152 (Parent study Main Cohort) (BIOLOGICAL), Placebo (Parent study Main Cohort) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05648110?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.